Literature DB >> 6732221

In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

D L Van Caekenberghe, S R Pattyn.   

Abstract

The in vitro antimicrobial activity of ciprofloxacin (Bay o 9867) was compared with those of the other new fluorated piperazinyl-substituted quinoline derivatives: norfloxacin, ofloxacin, and pefloxacin, as well as with those of the earlier analogs, nalidixic acid and oxolinic acid. Virtually no resistance against the new fluorated piperazinyl-substituted quinoline derivatives was observed. As a rule, ciprofloxacin was about four times more active in vitro than the other new fluorated piperazinyl-substituted quinoline derivatives. The antibacterial spectrum of the new fluorated piperazinyl-substituted quinoline derivatives included, among other susceptible species, Pseudomonas aeruginosa, Streptococcus faecalis, Staphylococcus spp., and members of the family Enterobacteriaceae. In the case of ciprofloxacin, ofloxacin, and perfloxacin, anaerobes were included in the antibacterial spectrum as well. There was no cross resistance between the earlier analogs and the new fluorated piperazinyl-substituted quinoline derivatives. Regression analysis of MIC pairs for individual strains illustrated almost mathematical correlation between the antimicrobial activities of the quinoline derivatives.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732221      PMCID: PMC185569          DOI: 10.1128/AAC.25.4.518

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

2.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

3.  [A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)].

Authors:  Y Goueffon; G Montay; F Roquet; M Pesson
Journal:  C R Seances Acad Sci III       Date:  1981-01-05
  3 in total
  60 in total

1.  Ciprofloxacin concentration in the rabbit aqueous humor and vitreous following intravenous and subconjunctival administration.

Authors:  W Behrens-Baumann; J Martell
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist.

Authors:  E E Camargo; S Sostre; B Sadzot; I Shafique; Z Szabo; J M Links; R F Dannals; H N Wagner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Internal medicine: new antibiotics.

Authors:  J Silva
Journal:  West J Med       Date:  1985-07

4.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

6.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Effect of oral ofloxacin on fecal bacteria in human volunteers.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

8.  Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice.

Authors:  S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.